FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?

Fierce Pharma·May 7

This story is reported by Fierce Pharma. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

FDA to reconsider treatment for rare cancer after its surprise rejection

STAT·May 7

2

Orca Bio makes a splash with FDA approval for cell therapy Tregzi. Could an IPO come next?

Fierce Pharma·Jul 1